Although alternatives are increasingly becoming available, apprehension and regulatory demands remain key obstacles to the use of non-animal-based models in preclinical pharmaceutical testing.
Why Is Animal Testing Still With Us?
Alternative Models Need To Be Standardized For Greater Adoption
Despite increased openness by regulators and technological progress, the adoption of alternatives to animal testing remains challenging. The need for data validation by agencies and companies is a big factor.
More from Global Vision
• By
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
• By
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
• By
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
• By
The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.